Womab
Pertuzumab
Vial: 420 mg
Therapeutic Areas
Oncology
Indications
- HER2-Positive Metastatic Breast Cancer
- HER2-Positive Early Breast Cancer
Shelf life
3 years
Launched Year
2025
Available in
1 Country
What is Womab?
Womab (pertuzumab) is a monoclonal antibody used in the treatment of HER2-positive breast cancer, including metastatic breast cancer and early breast cancer. It works in combination with trastuzumab and chemotherapy.
Storage Conditions
2-8 degrees Celsius (refrigerate), Do not freeze
Presentation
Vial containing concentrate for solution for infusion
Route of Administration
Intravenous (IV)(upon prescription only and administered by a healthcare provider.)
Indications
How Pertuzumab works?
Mechanism of Action
Pertuzumab binds to the HER2 receptor, a key driver of cell growth and differentiation in HER2-positive cancers. By inhibiting the dimerization of HER2 with other HER receptors, pertuzumab prevents the activation of downstream signaling pathways that promote tumor cell proliferation and survival. This mechanism helps to inhibit tumor growth and improve patient outcomes.
We Meet Global Standards
- Publication
- 31-03-2017
Long‑term outcome of diffuse large B‑cell lymphoma: Impact of biosimilar rituximab and radiation
- Publication
- 13-01-2017
Safety and Efficacy of an Anti‑CD20 Monoclonal Antibody (Reditux) In Indian Patients with Seropositive Rheumatoid Arthritis
- Publication
- 25-03-2022
Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
- Publication
- 18-07-2021